Search results for "GFR"

showing 10 items of 206 documents

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clin…

2014

Abstract: Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the phenomenon of 'oncogene addiction', with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for direct comp…

Oncologymedicine.medical_specialtyLung NeoplasmsEGFR; Erlotinib; Gefitinib; Lung cancer; NSCLC; Tyrosine kinaseSettore MED/06 - Oncologia MedicaEGFRAntineoplastic Agentsmedicine.disease_causeNSCLCErlotinib HydrochlorideGefitinibGrowth factor receptorPharmacokineticsCarcinoma Non-Small-Cell LungInternal medicineHumansMedicineLung cancerLungProtein Kinase InhibitorsneoplasmsTyrosine kinasebusiness.industryGefitinibHematologyOncogene Addictionmedicine.diseaserespiratory tract diseasesErbB ReceptorsOncologyErlotinibQuinazolinesHuman medicineErlotinibLung cancerbusinessCarcinogenesisTyrosine kinasemedicine.drug
researchProduct

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

2022

Background: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studied the frequency and clinical characteristics in a real-world and population-based setting. Methods: Patients from three Nordic population-based cohorts and the real-life RAXO-study were combined. RAS and BRAF tests were performed in routine healthcare, except for one cohort. The dataset consisted of 2,559 patients, of which 1,871 could be accurately classified as KRAS, NRAS, and BRAF-V600E. Demog…

Cancer och onkologireal-worldendocrine system diseasesEGFR3122 CancersKRAS mutationKRAS-G12C mutationKRAS MUTATIONScolorectal cancersuolistosyövät3126 Surgery anesthesiology intensive care radiologyTUMORSdigestive system diseasesetäpesäkkeetmetastaticpopulation-basedPOOLED ANALYSISRAS MUTATIONSsyöpägeenitCancer and Oncologymutaatiotkohorttitutkimusneoplasmspaksusuolisyöpä
researchProduct

Structural performances of pultruded GFRP emergency structures – Part 1: Experimental characterization of materials and substructure

2019

Abstract This paper presents an experimental study in the field of structures made of pultruded fiber reinforced polymers (FRP) elements to be used for emergency purposes. A preliminary design of a 3D pultruded glass fiber reinforced polymer structure is presented with the mechanical characterization of the constituting elements. The axial and flexural properties of laminate and I-shaped GRFP profiles are discussed considering the short term creep. In a companion paper, the benefits, the limits and the reliability of the structure analyzed for emergency applications are discussed. In details, the numerical structural analysis of the full-scale 3D model is described followed by the experimen…

Materials science/dk/atira/pure/subjectarea/asjc/2200/2205Experimental testsGlass-fibre-reinforced polymer GFRP pultruded profileFlexural strengthEmergency structureExperimental testPultrusionFiber/dk/atira/pure/subjectarea/asjc/2500/2503Civil and Structural EngineeringComposite structuresbusiness.industryGlass fiber reinforced polymerStructural engineeringFibre-reinforced plasticCharacterization (materials science)Emergency structuresSettore ICAR/09 - Tecnica Delle CostruzioniSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiCreepPultrusionComposite structureCeramics and CompositesSubstructurebusinessGlass-fibre-reinforced polymer GFRP pultruded profiles
researchProduct

Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis

2018

Background: Recent studies evaluated the diagnostic accuracy of circulating tumor DNA (ctDNA) analysis in the detection of epidermal growth factor receptor (EGFR) mutations from plasma of NSCLC patients, overall showing a high concordance as compared to standard tissue genotyping. However it is less clear if the location of metastatic site may influence the ability to identify EGFR mutations. Objective: This pooled analysis aims to evaluate the association between the metastatic site location and the sensitivity of ctDNA analysis in detecting EGFR mutations in NSCLC patients. Methods: Data from all published studies, evaluating the sensitivity of plasma-based EGFRmutation testing, stratifi…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsGenotypeSettore MED/06 - Oncologia MedicaConcordanceEGFRintrathoracicReal-Time Polymerase Chain ReactionNSCLCMetastasisCirculating Tumor DNACohort Studies03 medical and health sciencesT790M0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineHumansmetastasisLiquid biopsyNeoplasm MetastasisLung cancerGenotypingextrathoracicEGFR; NSCLC; ctDNA; extrathoracic; intrathoracic; liquid biopsy; metastasisPharmacologyChi-Square Distributionliquid biopsybusiness.industryOdds ratioctDNAmedicine.diseaseConfidence intervalData AccuracyErbB Receptors030104 developmental biologyOncology030220 oncology & carcinogenesisMutationHuman medicinebusiness
researchProduct

2-Triazenoazaindoles: Α novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells

2012

Pancreatic cancer is a complex malignancy arising from the accumulation of genetic and epigenetic defects in the affected cells. Standard chemotherapy for patients with advanced disease shows only modest effects and is associated with considerable toxicity. Overexpression or aberrant activation of members of the epidermal growth factor receptor tyrosine kinase family, which includes EGFR and HER-2, occurs frequently and is associated with multiple drug resistance and decreased patient survival. In this study, we have investigated the therapeutic potential of AS104, a novel compound of the triazene class, with potential inhibitory effects on EGFR. We found that treatment of cells with AS104 …

Cancer ResearchProgrammed cell deathmedicine.medical_specialtyIndolesReceptor ErbB-2EGFRCellpancreatic cancer2-triazenoazaindoles pancreatic cancer cell death EGFR HER-2Down-RegulationApoptosisCell Growth ProcessesBiologyReceptor tyrosine kinasePancreatic cancerInternal medicineCell Line TumormedicineAutophagyHumansMolecular Targeted TherapyOncogeneCell growthCancerArticlesCell cyclemedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaErbB ReceptorsPancreatic Neoplasmsmedicine.anatomical_structureEndocrinologycell deathOncologyHER-2Cancer researchbiology.protein2-triazenoazaindolesTriazenesCarcinoma Pancreatic Ductal
researchProduct

Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations

2011

BACKGROUND: Human tumors transplanted into immunodeficient mice (xenografts) are good preclinical models, and it is important to identify possible systematic changes during establishment and passaging in mice. METHODS: High-resolution microarray-based comparative genomic hybridization (array CGH) was used to investigate how well a series of sarcoma xenografts, including 9 patient/xenograft pairs and 8 early versus late xenograft passage pairs, represented the patient tumor from which they originated. RESULTS: In all analyses, the xenografts were more similar to their tumor of origin than other xenografts of the same type. Most changes in aberration patterns were toward a more normal genome …

Cancer ResearchPathologymedicine.medical_specialtyMicroarraybiologyCancerPDGFRAbiology.organism_classificationmedicine.diseaseTransplantationNude mouseOncologyTumor progressionmedicineSarcomaComparative genomic hybridizationCancer
researchProduct

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.

2019

Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system. With no effective therapy, the prognosis for patients is terrible poor. It is highly heterogeneous and EGFR amplification is its most frequent molecular alteration. In this light, we aimed to examine the genetic heterogeneity of GBM and to correlate it with the clinical characteristics of the patients. For that purpose, we analyzed the status of EGFR and the somatic copy number alterations (CNAs) of a set of tumor suppressor genes and oncogenes. Thus, we found GBMs with high level of EGFR amplification, low level and with no EGFR amplification. Highly amplified tumors showed histological features of…

0301 basic medicineMaleCancer ResearchBiopsyL-amp GB EGFR-low amplified glioblastomamedicine.disease_causewt wildtypeMYBPC3 myosin-binding protein C0302 clinical medicineHIC1 hypermethylated in cancer 1Gene duplicationIn Situ Hybridization FluorescenceIDH2 isocitrate dehydrogenase 2MutationRB-pat RB signaling pathwayEGFRvIII epidermal growth factor receptor variant number IIIPAH phenylalanine hydroxylaseGBM glioblastoma IDH-wildtype (glioblastoma multiforme primary glioblastoma).ANOVA ANalysis Of VArianceN-amp GB EGFR-no amplified glioblastomaMiddle AgedCDKN2A cyclin-dependent kinase inhibitor 2Alcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisPrimary tumorImmunohistochemistryH-amp GB EGFR-high amplified glioblastomaErbB ReceptorsTKR-pat tyrosine-kinase receptors signaling pathway030220 oncology & carcinogenesisDisease ProgressionCDK6 cyclin-dependent kinase 6CDH1 Cadherin 1FemaleCREM cAMP response element modulatorIHC immunohistochemistryAdultOriginal articleDNA Copy Number VariationsCDKN1B cyclin-dependent kinase inhibitor 1BBiologyRARB retinoic acid receptor betaCNS central nervous systemlcsh:RC254-282IDH1 isocitrate dehydrogenase 1BCL2 B-cell cll/ lymphoma 2CNAs copy number algerationsWHO World Health Organization03 medical and health sciencesYoung Adultp53-pat p53 signaling pathwaymedicineBiomarkers TumorTMA tissue microarrayPTENHumansProtein kinase BPI3K/AKT/mTOR pathwaySurvival analysisAgedGenetic heterogeneityGene AmplificationGFAP glial fibrillary acidic proteinMLPA multiplex ligation-dependent probe amplificationmedicine.diseaseFISH fluorescence in situ hibridizationSurvival AnalysisCDKN2B cyclin-dependent kinase inhibitor 2BPTEN phosphatase and tensin homologEGFR epidermal growth factor receptorCNV-load load of copy number variations030104 developmental biologyMutationPARK2 parkinCancer researchbiology.proteinTCGA The Cancer Genome AtlasLARGE1 acetylglucosaminyltransferase-like protein 1GlioblastomaCHD7 Chromodomain Helicase DNA Binding Protein 7DAPI 4′6-diamidino-2-phenylindoleNeoplasia (New York, N.Y.)
researchProduct

The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer

2019

Targeted therapies have allowed for an individualized treatment approach in non-small-cell lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy depend on genetic identification of personal tumor profiles. Tissue biopsy is the gold standard for molecular analysis, but non-invasive or minimally invasive liquid biopsy methods are also now used in clinical practice, allowing for later monitoring and optimization of the cancer treatment. The inclusion of liquid biopsy in the management of NSCLC provides strong evidence on early treatment response, which becomes a basis for determining disease progression and the need for changes in treatment. Liquid biopsies can…

0301 basic medicineOncologymedicine.medical_specialtyTreatment responseCancer Researchmedicine.medical_treatmentEGFRprecision medicinePsychological interventionbiopsiabiomarkkeritReviewverenkiertoNSCLClcsh:RC254-282Targeted therapykeuhkosyöpä03 medical and health sciences0302 clinical medicineCirculating tumor cellInternal medicinemedicinecancerLiquid biopsyLung cancerpersonalized therapysyöpähoidotbusiness.industryDNActDNAdiagnostiikkalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrecision medicine3. Good healthsyöpäsolut030104 developmental biologyOncology030220 oncology & carcinogenesisNon small cellbusinessFrontiers in Oncology
researchProduct

Forecasting Molecular Features in IDH-Wildtype Gliomas: The State of the Art of Radiomics Applied to Neurosurgery

2023

Simple Summary The prognostic expectancies of patients affected by glioblastoma have remained almost unchanged during the last thirty years. Along with specific oncological research and surgical technical alternatives, corollary disciplines are requested to provide their contributions to improve patient management and outcomes. Technological improvements in radiology have led to the development of radiomics, a new discipline able to detect tumoral phenotypical features through the extraction and analysis of a large amount of data. Intuitively, the early foreseeing of glioma features may constitute a tremendous contribution to the management of patients. The present manuscript analyzes the p…

IDHWHO classificationCancer ResearchOncologyEGFRradiomicglioblastomaTERTpaneuploidiebrain tumorCancers
researchProduct

PROX1 transcription factor controls rhabdomyosarcoma growth, stemness, myogenic properties and therapeutic targets

2022

Funding Information: ACKNOWLEDGMENTS. We would like to thank Dr. Tuomas Tammela and Dr. Monika Ehnmann for providing RMS cell lines and Dr. Jenny Högström for discussions and comments during the project. Kirsi Mattinen, Jefim Brodkin, Maxime Laird, Manon Gruchet, Ilse Paetau, Tanja Laakkonen, and Tapio Tainola are acknowledged for their excellent technical help. We also thank the Laboratory Animal Center at the University of Helsinki for expert animal care, the Biomedicum Imaging Unit for microscope support, the Biomedicum Functional Genomics Unit for the RNAseq experiments and the FIMM Technology Centre High Throughput Biomedicine for the drug sensitivity and resistance testing. Our first …

MultidisciplinarysarcomaFGFRPROX13122 CancersGenes HomeoboxReceptors Fibroblast Growth FactorsarkoomaGene Expression RegulationRhabdomyosarcomaHumanscancersyöpätauditmyogenesis3111 BiomedicineChildTranscriptomeProtein Kinase InhibitorsTranscription Factors
researchProduct